[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-stroke":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,73,100,130,161,189,210,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100492369","phase-3-assess-the-safety-and-efficacy-of-sovateltide-in-patients-with-acute-cerebral-ischemic-stroke-100492369","NCT05691244","Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke","A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.","RESPECT-ETB","Inclusion Criteria:\n\nA patient will be eligible for inclusion in the study if he\u002Fshe fulfills the following criteria:\n\n1. Adult males or females aged 18 - 80 years of age.\n2. Consent obtained per national laws and regulations, and in accordance with the applicable ethics committee requirements prior to study procedures.\n3. A stroke is ischemic in origin that is diagnosed clinically and\u002For radiologically confirmed by Computed Tomography (CT) scan or diagnostic magnetic resonance imaging (MRI) prior to enrolment. No hemorrhage as proved by cerebral CT\u002FMRI scan.\n4. Cerebral ischemic stroke patients presenting within 24 hours after the onset of symptoms with NIHSS score of ≥8 and \\\u003C20, NIHSS Level of Consciousness (1A) score \\\u003C2 at the time of screening. This includes cerebral ischemic stroke patients who completely recovered from earlier episodes before having a new or fresh stroke having a pre-stroke historical measure of mRS score of 0-2.\n5. The patient is \\\u003C24 hours from the time of stroke onset when the first dose of sovateltide is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when the patient was last seen or was self- reported to be normal.\n6. Reasonable expectation of availability to receive the full sovateltide\u002Fplacebo course of therapy and to be available for subsequent follow-up visits.\n\nExclusion Criteria:\n\nA patient will not be eligible for inclusion in this study if they meet any of the following exclusion criteria:\n\n1. Patients receiving endovascular therapy or is a candidate for any surgical intervention for the treatment of stroke, which may include but not limited to endovascular techniques.\n2. Patients classified as comatose are defined as a patient who requires repeated stimulation to attend or is obtunded and requires strong or painful stimulation to make movements (NIHSS Level of Consciousness (1A) score ≥2).\n3. Evidence of intracranial hemorrhage (intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan.\n4. Known pregnancy and lactating women.\n5. Known medical history of neurological (other than current acute ischemic stroke) or psychiatric condition that, in the investigator's opinion, would confound the neurological and functional evaluations, lead to further deterioration of neurological status, or interfere with participation in this study.\n6. Concurrent participation in any other therapeutic clinical trial.\n7. Evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol impair the assessment of outcome, or in which sovateltide therapy would be contraindicated or might cause harm to the patient.","80 Years",{"count":83,"type":21},514,[85],"PHASE3","Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.",[88,37],"Acute Ischemic Stroke",[90],"Endothelin B Receptors","2026-06-19",{"date":61,"type":64},{"date":94,"type":64},"2025-07-24",{"date":96,"type":21},"2026-11",{"name":98,"class":71},"Pharmazz, Inc.",54,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100310212","stroke-recovery-initiative---registry-for-stroke-research-studies-100310212","NCT03318432","Stroke Recovery Initiative - Registry for Stroke Research Studies","Stroke Recovery Initiative - Stroke Registry","* 18 years of age or older\n* Have suffered a stroke\n* Have ongoing symptoms as a result of the stroke",{"count":108,"type":21},60000,"5 Years","OBSERVATIONAL","The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.",[31,113,114,115,116,36,35,37,55],"Acute Stroke","Ischemic Stroke","Hemorrhagic Stroke","Subarachnoid Hemorrhage",[31,113,114,115,36,35,37,55,118],"Stroke Recovery","2025-09-26",{"date":121,"type":64},"2025-10-02",{"date":123,"type":64},"2013-02-09",{"date":125,"type":21},"2028-09",{"name":127,"class":128},"University of California, San Francisco","OTHER",1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":129},"100374570","cerebral-oxygen-metabolism-in-children-100374570","NCT04157179","Cerebral Oxygen Metabolism in Children","COMIC","Healthy Controls:\n\n* Healthy controls ages 3-50 years of age\n* Able to participate in MRI scan without sedation\n* Not currently pregnant\n* No significant psychiatric history, defined as having a severe psychiatric diagnosis, per PI discretion\n* No history of epilepsy\n* No history of stroke or cerebrovascular disease\n* May have occasional headaches if not taking a daily preventative medication for headaches\n* Not on vasodilatory medication, such as sildenafil or verapamil\n\nSickle Cell Anemia Participants:\n\n* Ages 3-50 years of age\n* Hb SS or SBeta-thal\n* Able to participate in MRI scan without sedation\n* Not currently pregnant\n* Not on vasodilatory medication, such as sildenafil or verapamil\n\nExtracorporeal Membrane Oxygenation (ECMO) Survivors:\n\n* Ages 3-50 years of age\n* History of cannulation for ECMO\n* Able to participate in MRI scan without sedation\n* Not currently pregnant\n* Not on vasodilatory medication, such as sildenafil or verapamil",true,"3 Years","50 Years",{"count":141,"type":21},350,[24],"The purpose of this research study is to better understand how blood flow and metabolism change can influence brain development in the early decades of life.\n\nWe will examine brain blood flow and metabolism using magnetic resonance imaging (MRI). The brain's blood vessels expand and constrict to regulate blood flow based on the brain's needs. The amount of expanding and contracting the blood vessels can do varies by age. The brain's blood flow changes in small ways during everyday activities, such as normal brain growth, exercise, or deep concentration. Significant illness or psychological stress may increase the brain's metabolic demand or cause other bigger changes in blood flow. If blood vessels are not able to expand to give more blood flow when metabolic demand is high, the brain may not get all of the oxygen it needs. In extreme circumstances, if the brain is unable to get enough oxygen for a long time, a stroke may occur. Sometimes small strokes occur without other noticeable changes and are only detectable on an MRI. These are sometimes called \"silent strokes.\" In less extreme circumstances, not having as much oxygen as it wants may cause the brain to grow and develop more slowly than it should.\n\nOne way to test the ability of blood vessels to expand is by measuring blood flow while breathing in carbon dioxide. Carbon dioxide causes blood vessels in the brain to dilate without increasing brain metabolism.\n\nDuring this study participants may be asked to undergo a blood draw, MRI, and potential neuropsychological assessments. It is also possible that the study team will use a special mask to control the amount of carbon dioxide the participants breathe in so they don't breathe in too much.",[145,37],"Sickle Cell Disease",[147,148,149,150,151],"extracorporeal membrane oxygenation","cerebrovascular reactivity","sickle cell disease","healthy controls","magnetic resonance imaging","2025-09-03",{"date":154,"type":64},"2025-09-11",{"date":156,"type":64},"2019-10-17",{"date":158,"type":21},"2027-12",{"name":160,"class":128},"Washington University School of Medicine",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":129},"100588894","effect-of-action-observation-therapy-in-comparison-to-motor-relearning-program-on-balance-and-mobility-among-subacute-stroke-patients-100588894","NCT06947343","Effect of Action Observation Therapy in Comparison to Motor Relearning Program on Balance and Mobility Among Subacute Stroke Patients","Inclusion Criteria:\n\n* Both genders, male and female\n* Ischemic stroke patients\n* Age 45 years and above\n* MMSE\\>24\n* Able to stand independently for 1 minute\n* Patient can maintain starting sitting static position for 10 seconds without arm rest\n\nExclusion Criteria:\n\n* Any other neurological disorder\n* Orthopedic conditions(fracture) affecting balance and mobility\n* Visual or auditory impairments","45 Years",{"count":169,"type":21},30,[24],"This study is a randomized controlled trial. The purpose of this study is to determine the effect of Action Observation Therapy in Comparison to a Motor Relearning Program on Balance and Mobility among subacute stroke patients.",[173,37,174,175,176],"Subacute Stroke","Cerebrovascular Stroke","Posture","Functional Performance",[178,179],"Action observation therapy","Motor relearning program","2025-04-20",{"date":182,"type":64},"2025-04-27",{"date":184,"type":64},"2024-07-22",{"date":186,"type":21},"2025-06-15",{"name":188,"class":128},"Foundation University Islamabad",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":129},"100487311","telerehabilitation-early-after-stroke-100487311","NCT05625438","Telerehabilitation Early After Stroke","Bedside Telerehabilitation Early After Stroke","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Stroke that is radiologically verified, due to ischemia or to intracerebral hemorrhage, and with time of stroke onset \\\u003C30 days prior to enrollment; or traumatic brain injury.\n3. Unilateral arm motor deficits that are neither trivial (no arm weakness) or devastating (arm plegia). This requires that the baseline Box \\& Block Test score with affected arm to be at least 1 block in 60 seconds but no more than 90% of the number of blocks with the good arm.\n4. Possess enough arm movement to participate in therapy\n5. Informed consent signed by the subject\n6. Able to follow simple instructions\n7. Study participation is not likely to be significantly limited by agitated behavior\n\nExclusion Criteria:\n\n1. A major, active, coexistent neurological or psychiatric disease that would limit study participation, e.g., advanced dementia\n2. Expectation that patient's cognitive status will likely interfere substantially with playing assigned games or exercises\n3. Deficits in communication that interfere with reasonable study participation\n4. Lacking visual acuity, with or without corrective lens, of 20\u002F50 or better in at least one eye\n5. Subject does not speak sufficient English to comply with study procedures\n6. Shoulder pain that in the judgement of the study team is likely to substantially limit the amount of telerehabilitation therapy completed",{"count":197,"type":21},20,[24],"The goal of this clinical trial is to assess the safety and feasibility of providing extra doses of rehabilitation therapy for persons with a recent stroke. The therapy treatment targets to improve arm function by introducing telerehabilitation to the bedside of participants during the inpatient rehab admission period. Participants will use a newly developed functional training system (HandyMotion) to access therapy treatment program directly from their hospital room. HandyMotion is a sensor-based training system that can connect to the TV set in the hospital room, enabling patients to access their therapy training program to practice rehab-oriented games and exercises ad libitum, at any time of the day.",[37],"2024-12-03",{"date":203,"type":64},"2024-12-06",{"date":205,"type":64},"2022-12-19",{"date":207,"type":21},"2025-12",{"name":209,"class":71},"TRCare, Inc.",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":129},"100526318","super-resolution-ultrasound-of-the-brain-in-3d-100526318","NCT06133179","Super-Resolution Ultrasound of the Brain in 3D","Pilot Study of the Characterization of Subacute Ischemic Cerebrovascular Accidents in the Region of the Middle Cerebral Artery by 3D Ultrasound Localization Microscopy (ULM) with a Research Ultrasound System and Non-marketed 2D Matrix Probe.","ESRC3D","Inclusion Criteria:\n\n* Patient aged 18 and over\n* Hospitalized patient with ischemic stroke in the deep territory of the middle cerebral artery\n* Patient with lesion observable on MRI\n* Patient included between 24 hours and 7 days after the ischemic stroke\n* Patient with a temporal window which allows soundproofing of the polygon of Willis and the middle cerebral artery\n* Patient having signed free, informed and written consent\n* Patient affiliated to a social security system (excluding AME)\n\nExclusion Criteria:\n\n* Contralateral middle cerebral artery territory stroke or contralateral middle cerebral artery occlusion\n* Patient with contraindication to Doppler ultrasound with contrast (right-left shunt, severe pulmonary arterial hypertension)\n* Patient with hypersensitivity to the active princip of Sonovue (sulfur hexafluoride) or these excipients\n* Patient with uncontrolled systemic hypertension\n* Patient with respiratory distress syndrome\n* Patient under guardianship or curatorship\n* Pregnant or breastfeeding patient (positive blood pregnancy test during hospitalization)\n* Patient with damaged skin at the temporal level\n* Patient having presented in the 7 days preceding inclusion an acute coronary syndrome or suffering from unstable ischemic heart disease",{"count":197,"type":21},[24],"The goal of this proof of concept study is to determine if the visualization of the middle cerebral artery and its perforators, through 3D transtemporal ultrasound imaging, is possible thanks to an off-line analysis by 3D ultrasound localization microscopy. Visualization of these vessels would allow us to conclude on the presence, or absence, of an ischemic stroke in the region of the middle cerebral artery.\n\nTo answer the question asked, 20 participants who suffered a stroke will carry out a transtemporal ultrasound examination specifically for research in the 7 days following his stroke. The data obtained will be analyzed by the CNRS medical imaging laboratory, in order to characterize the presence of a stroke and to compare the data obtained with that of standard examinations (CT and MRI).",[37],"2024-09-03",{"date":224,"type":64},"2024-09-19",{"date":226,"type":64},"2024-03-22",{"date":228,"type":21},"2025-02",{"name":230,"class":128},"Assistance Publique - Hôpitaux de Paris",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":129},"100486447","deep-enhanced-imaging-in-stroke-and-vascular-neurology-100486447","NCT05614193","Deep Enhanced Imaging in Stroke and Vascular Neurology","Inclusion Criteria:\n\n* suspecting to have experienced stroke or cerebral ischemia and needed to undergo brain imaging and vascular imaging including CT or MRI\n* no history of kidney failure\n* a minimum age of 18 years\n* obtained written informed consent\n\nExclusion Criteria:\n\n* severe movement artifacts\n* incidental finding of tumor lesion or craniocerebral surgery history\n* poor imaging failed to perform deep learning method\n* women who pregnancy","100 Years",{"count":239,"type":21},1000,"To investigate the performance of enhanced computed tomography (CT) or magnetic resonance (MR) imaging by deep learning relative to conventional CT or MR imaging in brain stroke and vascular neurology. We expect that the deep enhanced imaging method can shorten the time stay in the imaging session of stroke patients, optimize the overall imaging quality and improve the patients' care in imaging session.",[242,37,243],"Radiology","Vascular Diseases",[245,246,247,248,249],"Deep learning","Medical imaging","Cerebral stroke","Cerebrovascular disease","Vascular imaging","2023-02-07",{"date":252,"type":64},"2023-02-08",{"date":254,"type":64},"2022-12-01",{"date":256,"type":21},"2027-12-31",{"name":258,"class":128},"Chinese PLA General Hospital"]